Publication: Memory B cells: A proposed new immunological correlate for protective efficacy of Japanese encephalitis vaccine
4
item.page.dc.date.issued
2013-08-01
item.page.dc.type
item.page.dc.identifier.issn
17448395
14760584
14760584
item.page.dc.identifier.doi
item.page.dc.identifier.other
2-s2.0-84887805523
item.page.dc.rights
Mahidol University
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Expert Review of Vaccines. Vol.12, No.8 (2013), 871-873
punsarn.item.page.citation
Eiji Konishi Memory B cells: A proposed new immunological correlate for protective efficacy of Japanese encephalitis vaccine. Expert Review of Vaccines. Vol.12, No.8 (2013), 871-873. doi:10.1586/14760584.2013.814828 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/31250
Research Projects
Organizational Units
Authors
Journal Issue
relationships.isThesisOf
item.page.dc.title
Memory B cells: A proposed new immunological correlate for protective efficacy of Japanese encephalitis vaccine
item.page.dc.contributor.author
item.page.dc.contributor.other
item.page.dc.description.abstract
Evaluation of: Larena M, Prow NA, Hall RA, Petrovsky N, Lobigs M. JE-ADVAX Vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8+T cells and pre-exposure neutralizing antibody. J. Virol. 87(8), 4395-4402 (2013). Japanese encephalitis (JE) virus requires dissemination within the host via the circulation for disease development. Thus, a serum-neutralizing antibody is an effective factor to protect against disease. Current licensed JE vaccines induce neutralizing antibodies and titers of 1:10 or higher are the recommended immunological correlate of protection. In this paper, the authors demonstrated, using a highly susceptible knockout mouse model, that memory B cells are required for disease protection and that detectable neutralizing antibodies at the time of challenge are dispensable. The authors proposes that the extent of memory B cells would be an alternative and better immunological correlate for evaluating the efficacy of JE vaccine candidates in clinical trials. © 2013 Informa UK Ltd.
